Share:
Basel, 22 April 2021 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and GenMark Diagnostics, Inc. today announced that Roche s wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) at a price of USD 24.05 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 21 April 2021 and was not extended.
Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of approximately 61,201,761 shares of GenMark s common stock were validly tendered and not validly withdrawn in the tender offer (excluding shares tendered by notice of guaranteed delivery for which certificates have not yet been received ), which represent approximately 82.89% of the total number of shares of GenMark s common stock outstanding.
Press Release: Roche signs definitive merger agreement with GenMark Diagnostics, Inc , to access novel technology to test for broad range of pathogens with one patient sample
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Roche signs definitive merger agreement with GenMark Diagnostics, Inc , to access novel technology to test for broad range of pathogens with one patient sample
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
F Hoffmann-La Roche Ltd: Roche signs definitive merger agreement with GenMark Diagnostics, Inc , to access novel technology to test for broad range of pathogens with one patient sample
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels
Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients
CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in
Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Identification (BCID) Panels. The study, “Evaluation of Microbiological Performance and the Potential Clinical Impact of the ePlex
® Blood Culture Identification Panels for the Rapid Diagnosis of Bacteremia and Fungemia,” looked prospectively at the identification of pathogens and antimicrobial resistance genes, as well as retrospectively analyzing clinical outcomes, based on ePlex BCID Panel